IL33 rs1342326 gene variation is associated with allergic rhinitis at school age after infant bronchiolitis
First published: 18 January 2020
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/apa.15175
Abstract
Aim
Interleukin (IL)‐33, encoded by the IL33 gene, is associated with allergy and asthma. We evaluated IL33 rs1342326 polymorphism in relation to asthma, asthma medication and allergic rhinitis after infant bronchiolitis.
Methods
IL33 rs1342326 polymorphism was studied in children, who were hospitalised for bronchiolitis at age younger than six months, and who were prospectively followed until 5‐7 years (N=141) and 11‐13 years (N=125) of ages.
Results
Presence of the wild AA versus variant AC or CC genotypes of the IL33 rs1342326 showed no significant associations with previous or current asthma at the mean ages of 6.4 or 11.7 years. However, 22.5% of children with the variant genotype used inhaled corticosteroids at the 5‐7 years visit (adjusted OR 2.94, 95%CI 1.04‐8.33, vs. those 8.9% with the wild genotype). The variant IL33 rs1342326 genotype was associated with allergic rhinitis at 6.4 years (adjusted OR 2.17, 95%CI 1.01‐4.76) and 11.7 years (3.23, 1.18‐9.09) of ages.
Conclusion
The frequent use of asthma control medication in 6.4 years old children with IL33 rs1342326 polymorphism suggests that this variation may increase susceptibility to severe asthma at preschool age. The IL33 rs1342326 variant genotype was associated with a three‐fold risk of allergic rhinitis at school age.
No comments:
Post a Comment